These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34620061)

  • 1. Metabolite Identification in the Preclinical and Clinical Phase of Drug Development.
    Wu Y; Pan L; Chen Z; Zheng Y; Diao X; Zhong D
    Curr Drug Metab; 2021; 22(11):838-857. PubMed ID: 34620061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE; Lopez-Anaya A
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The early estimation of circulating drug metabolites in humans.
    Luffer-Atlas D
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):985-97. PubMed ID: 22681256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies.
    van den Broek MP; Groenendaal F; Egberts AC; Rademaker CM
    Clin Pharmacokinet; 2010 May; 49(5):277-94. PubMed ID: 20384391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests?
    Gao H; Jacobs A; White RE; Booth BP; Obach RS
    AAPS J; 2013 Oct; 15(4):970-3. PubMed ID: 23821354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phase.
    Haglund J; Halldin MM; Brunnström A; Eklund G; Kautiainen A; Sandholm A; Iverson SL
    Chem Res Toxicol; 2014 Apr; 27(4):601-10. PubMed ID: 24593263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling.
    Rowland Yeo K; Gil Berglund E
    Clin Pharmacol Ther; 2021 Nov; 110(5):1168-1171. PubMed ID: 33934342
    [No Abstract]   [Full Text] [Related]  

  • 9. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review.
    Loisios-Konstantinidis I; Paraiso RLM; Fotaki N; McAllister M; Cristofoletti R; Dressman J
    J Pharm Pharmacol; 2019 Apr; 71(4):699-723. PubMed ID: 30793317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs in control samples in nonclinical safety studies: a reconsideration.
    Zimmer D
    Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
    [No Abstract]   [Full Text] [Related]  

  • 11. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimising the potential for metabolic activation in drug discovery.
    Kalgutkar AS; Soglia JR
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):91-142. PubMed ID: 16922655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug metabolites in safety testing.
    Hastings KL; El-Hage J; Jacobs A; Leighton J; Morse D; Osterberg RE
    Toxicol Appl Pharmacol; 2003 Jul; 190(1):91-2;author reply 93-4. PubMed ID: 12831788
    [No Abstract]   [Full Text] [Related]  

  • 15. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
    Leclercq L; Cuyckens F; Mannens GS; de Vries R; Timmerman P; Evans DC
    Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
    Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
    Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data.
    Iegre J; Hayes MA; Thompson RA; Weidolf L; Isin EM
    Drug Metab Dispos; 2016 May; 44(5):732-40. PubMed ID: 26868617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of drug metabolites.
    Izumi T
    Drug Metab Pharmacokinet; 2011; 26(2):121-2. PubMed ID: 21532211
    [No Abstract]   [Full Text] [Related]  

  • 19. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH
    Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical strategies for the screening and evaluation of chemically reactive drug metabolites.
    Wen B; Fitch WL
    Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):39-55. PubMed ID: 19236228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.